An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial
Open Access
- 29 September 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Abstract
To explore the therapeutic potential of blocking thymic stromal lymphopoietin (TSLP) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), we conducted a phase 1b/2a, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of CM326, a monoclonal antibody against TSLP. We enrolled 84 eligible patients with uncontrolled CRSwNP and stratified them based on baseline tissue eosinophil count. Patients are assigned to receive CM326 220 mg (n = 40) or placebo (n = 20) every 2 weeks (Q2W) and CM326 220 mg (n = 20) or placebo (n = 4) every 4 weeks (Q4W) for 16 weeks. Subsequently, all patients continue on CM326 220 mg Q2W or Q4W for an additional 36 weeks, followed by a 12-week follow up. Primary endpoints are safety of CM326 and change from baseline in NPS at week 16 in patients with eosinophilic CRSwNP (ECRSwNP). Main secondary endpoints include the change from baseline in NPS at week 16 in non-eosinophilic CRSwNP (nonECRwNP) and pharmacodynamic markers. Throughout the 64-week study, all treatment-emergent adverse events (TEAEs) are mild or moderate. CM326 Q2W improves NPS in patients with ECRSwNP compared with placebo at week 16 (mean difference [95% CI], −1.2 [−2.3 to −0.1], P = 0.04), with sustained benefits during the open-label and follow-up periods. Notably, peripheral blood and tissue eosinophil counts and concentrations of plasma IL-13 and IL-5 are reduced by week 16 with the treatment of CM326 Q2W versus placebo. A post-hoc analysis demonstrates that all participants with baseline TSLP > 330 fg/mL achieve a substantial reduction in NPS by week 16 with the treatment of CM326 Q2W (mean difference vs. placebo: −1.75 [95%CI, −3.06 to −0.44], P = 0.01). Overall, CM326 is well tolerated and effective in patients with uncontrolled ECRSwNP. A baseline plasma TSLP level of 330 fg/mL may serve as a predictive marker for treatment efficacy of CM326. ClinicalTrials.gov Identifier: NCT05324137.Keywords
This publication has 28 references indexed in Scilit:
- Staphylococcus aureus Induces a Mucosal Type 2 Immune Response via Epithelial Cell–derived CytokinesAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomesAllergy, 2018
- Tezepelumab in Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2017
- Role of tissue eosinophils in chronic rhinosinusitis–associated olfactory lossInternational Forum of Allergy & Rhinology, 2017
- Cellular phenotyping of chronic rhinosinusitis with nasal polypsRhinology journal, 2016
- Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and OceaniaJournal of Allergy and Clinical Immunology, 2016
- Predictive Significance of Tissue Eosinophilia for Nasal Polyp Recurrence in the Chinese PopulationAmerican Journal of Rhinology & Allergy, 2015
- The Importance of Local Eosinophilia in the Surgical Outcome of Chronic Rhinosinusitis: A 3-Year Prospective Observational StudyAmerican Journal of Rhinology & Allergy, 2014
- Impact of Mucosal Eosinophilia and Nasal Polyposis on Quality‐of‐Life Outcomes after Sinus SurgeryOtolaryngology–Head and Neck Surgery, 2010
- Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polypsJournal of Allergy and Clinical Immunology, 2006